The Fly | ARWR

Arrowhead Pharmaceuticals

· ARWR

Dashboard

Financials

Ratios

Transcripts

Valuation

Monday

Arrowhead receives MAA in the EU for REDEMPLO

ARWR

Jun 22, 12:34 PM

Over a week ago

Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE

ARWR

May 27, 7:07 AM

Arrowhead presents clinical cardiometabolic data at EAS Congress

ARWR

May 26, 10:10 AM

Arrowhead price target raised by $11 at Bernstein, here's why

ARWR

May 13, 6:27 AM

Arrowhead price target raised by $10 at Chardan, here's why

ARWR

May 8, 4:31 AM

Arrowhead reports Q2 EPS (93c), consensus ($1.11)

ARWR

May 7, 4:34 PM

Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma

May 5, 8:04 AM

Arrowhead announces Australian TGA approved Redemplo for FCS

ARWR

May 1, 7:31 AM

Arrowhead initiated with bullish view at JPMorgan, here's why

ARWR

May 1, 4:42 AM

Arrowhead announces EMA recommended approval of Redemplo

ARWR

Apr 24, 6:41 AM

Intel upgraded, Reddit initiated: Wall Street's top analyst calls

+13

Apr 21, 10:03 AM

Arrowhead just upgraded at Morgan Stanley, here's why

ARWR

Apr 21, 5:07 AM

Arrowhead price target raised by $12 at BofA, here's why

ARWR

Apr 20, 9:36 AM

Arrowhead presents long-term efficacy, safety data for plozasiran

ARWR

Mar 29, 11:55 AM

Wave data brings questions about Arrowhead 'back to center stage,' says Leerink

Mar 26, 11:26 AM

Arrowhead price target lowered by $3 at BofA, here's why

Mar 26, 11:17 AM

Arrowhead price target lowered by $3 at Morgan Stanley, here's why

ARWR

Feb 6, 10:40 AM

ADT Inc. to replace Arrowhead in S&P 600 at open on 2/9

Feb 4, 5:21 PM

Arrowhead to replace Ciena in S&P 400 at open on 2/9

Feb 4, 5:20 PM

Arrowhead doses first patient in ARO-DIMER-PA trial

ARWR

Jan 27, 7:44 AM

Arrowhead price target raised by $40 at B. Riley, here's why

ARWR

Jan 22, 8:20 AM

Arrowhead price target raised by $15 at H.C. Wainwright, here's why

ARWR

Jan 21, 9:49 AM

Arrowhead price target raised by $10 at Piper Sandler, here's why

ARWR

Jan 13, 7:16 AM

Proprietary TRiM™ Platform Technology: Arrowhead's Targeted RNAi Molecule (TRiM™) platform provides a highly differentiated and efficient delivery system for RNAi therapeutics, enabling targeted delivery to various cell types beyond the liver.

Broad and Diverse Pipeline: The company maintains a deep pipeline with multiple drug candidates in different stages of development across a wide range of therapeutic areas, diversifying risk and expanding potential market opportunities.

Strategic Pharma Partnerships: Collaborations with major pharmaceutical companies (e.g., Janssen, Amgen, Takeda, GSK) provide significant non-dilutive funding, external validation, and leverage for broad development and commercialization.

Clinical Trial Failure Risk: Their drug candidates may fail to demonstrate sufficient efficacy or safety in clinical trials, leading to a halt in development.

Regulatory Approval Uncertainty Risk: Even if clinical trials are successful, their drug candidates may not receive necessary regulatory approvals from agencies like the FDA or EMA.

Intense Competition Risk: Arrowhead faces significant competition from other pharmaceutical and biotechnology companies developing treatments for similar indications, potentially impacting market share and pricing.

Charts

Clinical Trial Failure Risk: Their drug candidates may fail to demonstrate sufficient efficacy or safety in clinical trials, leading to a halt in development.

Regulatory Approval Uncertainty Risk: Even if clinical trials are successful, their drug candidates may not receive necessary regulatory approvals from agencies like the FDA or EMA.

Monday

Arrowhead receives MAA in the EU for REDEMPLO